arrow
M

Michihisa Moriguchi

Kyoto Prefectural University of Medicine
H指数:33
被引数:4,340

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Durable Disease Control With Atezolizumab Plus Bevacizumab but Limited Post-Progression Outcomes: A Multicenter Real-World Study in Advanced Hepatocellular Carcinoma

阿特珠单抗联合贝伐珠单抗可持久控制疾病,但进展后结局有限:一项多中心真实世界研究在晚期肝细胞癌中的应用

2026-02-180
OAAI
Atezolizumab Plus Bevacizumab for TACE-Unsuitable Intermediate-Stage HCC Beyond Up-To-7 Criteria: Final Analysis of REPLACEMENT

阿替利珠单抗联合贝伐珠单抗用于不适合TACE治疗的超出Up-To-7标准的中间阶段肝癌:REPLACEMENT研究的最终分析

2025-11-030
OAAI
Protocol of the IMPACT study: randomized, multicenter, phase 3 study evaluating the efficacy of immunotherapy (Atezolizumab) plus anti-VEGF therapy (Bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma
2025-03-110
OAAI
Evaluating two rechallenge strategies of immune checkpoint inhibitors: Durvalumab plus tremelimumab in advanced hepatocellular carcinoma

评估免疫检查点抑制剂的两种再攻击策略: Durvalumab联合tremelimumab治疗晚期肝细胞癌

2025-01-150
OA
Clinical significance of cachexia index determined by bioelectrical impedance analysis in patients with gastrointestinal cancer

生物电阻抗分析法测定胃肠道恶病质指数的临床意义

2024-12-310
OA
Final analysis of the REPLACEMENT study: a phase II study of atezolizumab plus bevacizumab (atezo plus bev) for patients (pts) with Transcatheter arterial chemoembolization (TACE)-unsuitable intermediate-stage hepatocellular carcinoma (HCC) beyond the up-to-seven criteria

REPLACEMENT研究的最终分析:一项关于阿替利珠单抗联合贝伐珠单抗(atezo plus bev)治疗经肝动脉化疗栓塞(TACE)不适宜的超出“七例标准”的中期肝细胞癌(HCC)患者的II期研究

2024-12-011
PRE
Hepatocyte-specific GDF15 overexpression improves high-fat diet-induced obesity and hepatic steatosis in mice via hepatic FGF21 induction

肝细胞特异性GDF15过表达通过肝脏FGF21诱导改善高脂饮食诱导的小鼠肥胖和肝脂肪变性

2024-10-143
OAAI
Ramucirumab for advanced hepatocellular carcinoma in the current real world: a Japanese single-arm study post-REACH-2 (The R-evolution study)
2024-06-060
OAAI
Safety/efficacy of atezolizumab plus bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma

阿特珠单抗联合贝伐单抗在不可切除肝细胞癌抗血小板/抗凝治疗中的安全性/有效性

2024-06-042
PRE
IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
2023-11-012
PRE
A Phase 2, Prospective, Multicenter, Single-arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-stage Hepatocellular Carcinoma: TACTICS-L Trial
2023-06-0536
OAAI